Abliva AB Interim Report January – June 2024
FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Press releases
Abliva AB Interim Report January – June 2023
The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354
Abliva AB Interim Report January – June 2022
SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Abliva AB Interim Report January – June 2021
Second quarter summary
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
NeuroVive Pharmaceutical AB Interim report January – June 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio
NeuroVive Pharmaceutical AB Interim report January – June 2017
Strategic in-licensing broadens the project portfolio
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015
Negative top-line result of phase III study and continued progress in other clinical projects
NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014
NeuroVive's research wins award at international research symposium
NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013
Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...